Regeneron Pharmaceuticals · Operating Cash Flow (Statement)

Latest reported$4.44Bperiod endingJun 30, 2026

REGN Cash from Operations (-$6.80M → $4.44B)

Annual operating cash flow (statement)

High-resolution chart · PNG

REGN operating cash flow (statement) history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Regeneron Pharmaceuticals Operating Cash Flow (Statement) — Annual fiscal periods (USD)
Period ending	Operating Cash Flow (Statement) (USD)
Dec 31, 2025	4,978,900,000
Dec 31, 2024	4,420,500,000
Dec 31, 2023	4,594,000,000
Dec 31, 2022	5,014,900,000
Dec 31, 2021	7,081,300,000
Dec 31, 2020	2,618,100,000
Dec 31, 2019	2,430,000,000
Dec 31, 2018	2,195,100,000
Dec 31, 2017	1,307,100,000
Dec 31, 2016	1,485,900,000
Dec 31, 2015	1,330,780,000
Dec 31, 2014	752,435,000
Dec 31, 2013	588,596,000
Dec 31, 2012	-74,615,000
Dec 31, 2011	-141,682,000
Dec 31, 2010	96,344,000
Dec 31, 2009	-72,230,000
Dec 31, 2008	-89,086,000
Dec 31, 2007	27,372,000
Dec 31, 2006	23,075,000
Dec 31, 2005	-30,296,000
Dec 31, 2004	-16,909,000
Dec 31, 2003	-6,133,000
Dec 31, 2002	-110,523,000
Dec 31, 2001	-57,320,000
Dec 31, 2000	-27,910,000
Dec 31, 1999	-13,800,000
Dec 31, 1998	-10,200,000
Dec 31, 1997	-6,100,000
Dec 31, 1996	-20,300,000
Dec 31, 1995	-18,200,000
Dec 31, 1994	-20,500,000
Dec 31, 1993	-30,100,000
Dec 31, 1992	-17,200,000
Dec 31, 1991	-6,800,000